Characterization of intestinal fungal community diversity in people living with HIV/AIDS (PLWHA)

Table 1 Clinical data of each group

Clinical data	CON (n = 12)	HIV (n = 41)	P-value
Age (year)	51.17 ± 7.38	47.65 ± 12.17	0.308
Gender (Male/Female)	7/5	28/13	0.156
Diet
Coarse cereals			0.261
^aFrequent	1 (8.3%)	4 (9.8%)
^bOccasional	9 (75.0%)	31 (75.6%)
^cRare	2 (16.7%)	6 (14.6%)
Vegetable			0.541
Frequent	4 (33.3%)	10 (24.4%)
Occasional	8 (66.7%)	28 (68.3%)
Rare	0 (0.0%)	3 (7.3%)
Fruit			0.639
Frequent	5 (41.7%)	16 (39.0%)
Occasional	7 (58.3%)	22 (53.7%)
Rare	0 (0.0%)	3 (7.3%)
Oily foods			0.367
Frequent	1 (8.3%)	2 (4.9%)
Occasional	8 (66.7%)	31 (75.6%)
Rare	3 (25.0%)	8 (19.5%)
BMI (kg/m²)	24.5 ± 3.2	22.1 ± 2.5	0.145
Smoking	2 (16.7%)	5 (12.2%)	0.652
Drinking	1 (8.3%)	2 (4.9%)	0.569
Transmission route	Not Applicable		Not Applicable
Blood transmission		20 (48.8%)
Heterosexual behavior		15 (43.9%)
Homosexual behavior		2 (4.9%)
Intravenous drug injection		1 (2.4%)
HAART scheme	Not Applicable		Not Applicable
^d3TC+TDF + EFV		28 (68.3%)
^eEVG/c/FTC/TAF		8 (19.5%)
^fZidovudine and Lamivudine Tablets + LPV/r		5 (12.2%)

Note: ^a Frequent indicated ≥ 5 times per week
^b Occasional indicated 2–4 times per week
^c Rare indicated ≤ 1 time per week
^d 3TC + TDF + EFV refers to a combination therapy of three drugs, Efavirz, Lamivudine and Tenofovir
^e EVG/c/FTC/TAF refers to a combination of four drugs, Elvitegravir, Cobicistat, Emtricitabine and Tenofovir alafenamide
^f Zidovudine tablets are a drug combination of Lamivudine and Zidovudine. LPV/r is a drug combination of Lopinavir and Ritonavir

ISSN: 1742-6405